IPR protection

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

What patent protection does Gilead’s COVID-19 treatment Remdesivir have?

By Anders Heebøll-Nielsen, Michael Bech Sommer | Posted on April 30, 2020

On 29 April 2020 Gilead announced that its drug Remdesivir has a positive effect in the treatment of COVID-19 from a phase three trial of the drug. The investigation was so successful that for ethical reasons it was “unblinded” – the effect observed was so significant that retaining the group on placebo would prevent those...

Read more : What patent protection does Gilead’s COVID-19 treatment Remdesivir have?

Filed under: Insights

Tags: applications, Coronavirus, COVID-19, Gilead, IPR protection, patents, PCT, Remdesivir

Recent contributors

Ai-Leen Lim, Partner and Attorney at Law, Hong Kong SAR

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President

Julia Wang, Senior Associate and Attorney at Law, Beijing, China

Julia Wang

Senior Associate, Attorney at Law

Ylva Strandberg, Counsel and AU and NZ Patent Attorney, Stockholm, Sweden

Ylva Strandberg

Counsel, AU and NZ Patent Attorney

Hongyue Li, Senior Associate and China Patent Attorney, Beijing, China

Hongyue Li

Senior Associate, China Patent Attorney

Isa Böttiger, Associate and Attorney at Law, Stockholm, Sweden

Isa Böttiger

Senior Associate, Attorney at Law

Ylva Wikmark, Counsel and European Patent Attorney, Stockholm, Sweden

Ylva Wikmark

Counsel, European Patent Attorney